Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02662608 · ClinicalTrials.gov registry record · NA
Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC)
A NA study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT02662608: Completed NA study, sponsored by M.D. Anderson Cancer Center.
NCT02662608 is a NA study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02662608, a NA study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
The goal of this study is to start treatment with the NOTCH1 inhibitor brontictuzumab in an attempt to control tumors and prolong survival. The therapy involves participant being given the drug brontictuzumab to treat adenoid cystic carcinoma (ACC) with NOTCH 1 mutations. This is considered an investigational treatment.
Interventions
- DRUG Brontictuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2015-12-29 |
| Est. Completion | 2016-03-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02662608
The ClinicalTrials.gov registry entry for NCT02662608 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brontictuzumab is the first listed.
NCT02662608 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02662608 about?
NCT02662608 is a clinical study titled "Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC)". The goal of this study is to start treatment with the NOTCH1 inhibitor brontictuzumab in an attempt to control tumors and prolong survival. The therapy involves participant being given the drug brontictuzumab to treat adenoid cystic carcinoma (ACC) with NOTCH 1 mutations. This is considered an inves...
What is the current status of trial NCT02662608?
This trial is currently completed. It is a NA study. The enrollment target is 1 participants. The study started on 2015-12-29. Estimated completion is 2016-03-06.
What interventions are being tested in trial NCT02662608?
The interventions under investigation include: Brontictuzumab (DRUG).
Who is sponsoring clinical trial NCT02662608?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.